It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

C4X Discovery Holdings plc (C4XD) Ordinary Shares 1p

Sell:41.00p Buy:43.00p 0 Change: 2.00p (5.00%)
Market closed Prices as at close on 14 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:41.00p
Buy:43.00p
Change: 2.00p (5.00%)
Market closed Prices as at close on 14 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:41.00p
Buy:43.00p
Change: 2.00p (5.00%)
Market closed Prices as at close on 14 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • C4X Discovery signs exclusive licensing deal with Sanofi

    12 April 2021 08:41

    (Sharecast News) - C4X Discovery has signed an exclusive worldwide licensing agreement with Sanofi worth up to €414m (£357.84m), it announced on Monday, for its oral preclinical IL-17A inhibitor programme.

  • C4X Discovery CEO to be interim chair of UK Vaccine Taskforce

    8 December 2020 12:26

    (Sharecast News) - Drug discovery company C4X Discovery confirmed on Tuesday that its chief executive officer Clive Dix has stepped into the role of interim chair of the UK Vaccine Taskforce.

  • C4X losses widen as its revenue drops to nil

    7 January 2020 09:59

    (Sharecast News) - Drug discovery company C4X Discovery Holdings announced a fall in revenue to nil in its full-year results on Tuesday, from £7.06m in 2018, which the board said as driven entirely by the...

  • C4X makes solid progress across portfolio of programmes

    1 October 2019 10:15

    (Sharecast News) - Drug discovery company C4X Discovery Holdings announced progress across a number of key programmes in line with its strategy on Tuesday, reporting that it was continuing to progress its...

  • C4X upbeat as its molecule progresses with Indivior

    27 September 2019 15:39

    (Sharecast News) - Drug discovery company C4X Discovery Holdings noted an announcement on Friday that the National Institutes of Health (NIH) in the United States has granted Indivior's application...

  • E-Therapeutics and C4X upbeat on Parkinson's collaboration

    6 December 2018 16:04

    (Sharecast News) - Network-driven drug discovery company e-Therapeutics and C4X Discovery Holdings updated the market on their collaboration on Thursday, to identify novel intervention strategies for the...

  • C4X enters drug discovery AI deal with GTN

    29 November 2018 12:21

    (Sharecast News) - Drug discovery company C4X Discovery Holdings has entered into a partnership with GTN, a new player in the field of drug discovery artificial intelligence, initially focussing on...

  • C4X Discovery adds business and legal expertise to board

    4 July 2018 14:12

    (Sharecast News) - C4X Discovery on Wednesday appointed Eva-Lotta Allan and Natalie Walter to the roles of non-executive chairman of the board and non-executive director, respectively.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2021. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.